A Randomized Phase I/II Study With Gemcitabine and RTA 402 [CDDO Me] or Gemcitabine and Placebo for Patients With Unresectable Pancreatic Cancer.

Trial Profile

A Randomized Phase I/II Study With Gemcitabine and RTA 402 [CDDO Me] or Gemcitabine and Placebo for Patients With Unresectable Pancreatic Cancer.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 14 Nov 2016

At a glance

  • Drugs Bardoxolone methyl (Primary) ; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 14 Nov 2016 Results published in the Media Release
    • 13 Nov 2014 According to ClinicalTrial.gov record, treatment arms changed from 7 to 9, phase 2 cohorts arms added in treatment table.
    • 30 Nov 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top